News stories about Conatus Pharmaceuticals (NASDAQ:CNAT) have trended somewhat positive recently, according to Alpha One. The research group, a division of Accern, identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a news impact score of 0.19 on Alpha One’s scale. Alpha One also assigned media stories about the biotechnology company an impact score of 80 out of 100, indicating that recent media coverage is likely to have an effect on the stock’s share price in the near future.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) traded up 6.31% on Thursday, hitting $7.24. 1,347,286 shares of the company were exchanged. The firm’s 50-day moving average is $5.09 and its 200-day moving average is $3.63. The stock’s market capitalization is $189.46 million. Conatus Pharmaceuticals has a 52-week low of $1.45 and a 52-week high of $7.34.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, March 15th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by $0.03. During the same quarter in the prior year, the business posted ($0.30) EPS. Equities research analysts predict that Conatus Pharmaceuticals will post ($0.83) earnings per share for the current year.
A number of research analysts have recently weighed in on CNAT shares. FBR & Co restated an “outperform” rating and set a $16.00 price objective on shares of Conatus Pharmaceuticals in a research report on Wednesday, March 15th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Conatus Pharmaceuticals in a research report on Friday, March 17th. Stifel Nicolaus raised their price objective on Conatus Pharmaceuticals from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, December 20th. Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 14th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 price objective (up previously from $17.00) on shares of Conatus Pharmaceuticals in a research report on Friday, December 23rd. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Conatus Pharmaceuticals has an average rating of “Buy” and an average price target of $13.25.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/conatus-pharmaceuticals-cnat-earns-news-sentiment-score-of-0-19/1739561.html
Receive News & Ratings for Conatus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.